The Science Behind Fast, Lasting, Powerful Pain Relief & Much More with Industry-Leading Clinical Research Results


When nothing else works, as your first line of defense, target the underlying cause now with D'OXYVA.

Pain-free life is here. Beyond major clinical outcomes for mild to extremely severe conditions, even when strong opioid-based painkillers were ineffective, new and long-term users of D'OXYVA® reported relief of persistent long-term chronic pain in 2 - 7 days associated with:



    Chemo-, and radiation therapy

    Chronic wounds

    Arthritis, osteoporosis

    Migraine headaches

    Lower back

Impaired tissue perfusion denies oxygen and blood flow where it is needed most, preventing the delivery of nutrients, natural pain relief, and slowing the healing process.

Few people, however, suffer as much from poor circulation as those with high blood sugar, arthritis, osteoarthritis, venous insufficiency, and cardiovascular complications do.

A scientific paper titled "Impared Tissue Perfusion - A Pathology Common to Hypertension, Obesity, and Diabetes Mellitus" published in Circulation by the American Heart Association underscores this fact.

In various clinical studies, D'OXYVA (deoxyhemoglobin vasodilator) has achieved over 90%* elimination of all sorts of chronic pain in 100% of subjects either the same day or in a few days, such as from a very high 8 to a very low 1 on the Visual Analog Scale (VAS).

*Average results rounded for display, based on number of enrolled subjects in each clinical study with D'OXYVA.
Read Clinical Evidence

By expert opinion, Circularity Healthcare is bringing about a radical change in the standard of care, transdermal delivery, cardiovascular, and neuroscience widely across the healthcare system.

Circularity has layed the groundwork for an explosion of a large variety of clinical research into entirely new promising treatments, even for rare diseases.

Neuropathies are characterized by a progressive loss of nerve fiber function. A widely accepted definition of diabetic peripheral neuropathy is "the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after exclusion of other causes."

Pain is defined by the International Association of Pain as unpleasant sensory and emotional experience, associated with actual or potential tissue damage, or described in terms of such damage. Pain is always subjective.

Fibromyalgia (FM) is characterized by generalized muscle pain, low muscle strength and autonomic dysfunction.

The autonomic nervous system regulates the ‘automatic’ functions of the body such as heart rate responsiveness to changing physical equirements.

Heart rate variability (HRV) is reduced in individuals with FM increasing their risk for cardiovascular morbidity and mortality.

Complex regional pain syndrome (CRPS) according to the National Institute of Neurological Disorders and Stroke at the National Institutes of Health is when people also experience changes in skin temperature, skin color, or swelling of the affected limb.

This is due to abnormal microcirculation caused by damage to the nerves controlling blood flow and temperature. As a result, an affected arm or leg may feel warmer or cooler compared to the opposite limb. The skin on the affected limb may change color, becoming blotchy, blue, purple, pale, or red.

Microcirculation dysfunction is increasingly regarded by the mainstream medical, scientific, cosmetic, and alternative health care community as the underlying cause of nearly all health complications for both the young and elderly.

Poor circulation, especially poor microcirculation and its dysfunction in these people often result in high blood pressure, hypertension, neuropathy pain, ulcers, and even necrosis.

Restrictions in this form of circulation impede the flow of antibodies, white blood cells and platelets, and rob the skin and tissues of oxygen and much needed nutrients.

D'OXYVA® (deoxyhemoglobin vasodilator)

Researchers are continuously seeking out solutions that reduce these symptoms, and recent clinical research has revealed a uniquely promising, affordable, and non-opioid solution.

D'OXYVA® advanced, non-invasive, and non-opioid biotech solution has demonstrated significantly strengthening the body’s natural healing foundation: the autonomic nervous system (parasympathetic nerve activity) and the microcirculatory system.

D'OXYVA has been demonstrating fast, lasting, and powerful pain relief and numerous major health benefits in record time.

D'OXYVA has been reviewed, studied, and used at prestigious institutions around the world such as Penn State University, Florida State University, Valley Presbyterian Hospital, Hospital Kuala Lumpur, Airlangga University, Chulalongkorn University, University of Szeged, National Taipei University and others. References

Featured Free White Paper:
Industry-Leading Noninvasive Transdermal Microcirculatory Technology for Rapid Closure of Complex Wounds with Significant Pain Relief

Prof. Judy M. Delp, PhD, Florida State University U.S.A.

Human Clinical Trial Results Show Outsized Circulation & Clinical Outcomes

    D'OXYVA improved microcirculation (Skin Perfusion Pressure) in a statistically significant manner in 100% of subjects by about 15-100% from absolute baseline (median over 40%).

    Improvement in blood flow peaked uniformly within 1 hour after a single 5-minute delivery on their thumb, and subsequently lasted for over 4 hours.

    100% of enrolled subjects responded positively without adverse events after being monitored for a year after the study.

The above results have been successfully reproduced by other studies and in various test reports with D'OXYVA, victims of neuropathy, peripheral vascular complications, bodily injury, surgical complications, and various forms of pain reported significant reduction in symptoms and pain in 9 out of 10 cases, typically within a week, from an 8 to 1 on the Visual Analog Scale (VAS) by taking it once or twice a day.
Press release

9 out of 10 users reported significant long-term health benefits, after just 6-8 weeks of regular daily use.

Press release

D'OXYVA is a Non-Invasive Transdermal Delivery (NTD), Non-Significant Risk (NSR) device, and Circularity Healthcare is conducting high-quality, cutting-edge clinical trials with leading institutions, researches, and health practitioners around the world to establish evidence for a wide variety of scientific and clinical outcomes with D'OXYVA. Please contact us to participate in Circularity's Center of Excellence (COE) program.

Select the color of your D'OXYVA® - target the cause of your pain & condition without negative side effects

Back to Top ^

A Variety of Significant Outcomes Through Improved Tissue Perfusion

As the summary abstract presented at the 2013 Diabetic Foot Global Conference describes on this page, in a pilot study all subjects received a painless, five-minute D'OXYVA delivery through their thumb and their Skin Perfusion Pressure (i.e., microcirculation) was measured periodically for four hours afterward.

Subjects suffering from high blood sugar have reported neuropathy pain relief minutes after D'OXYVA was administered.

All subjects recorded significant increases in Skin Perfusion Pressure (i.e., microcirculation). In fact, nearly 33%* increase on average from absolute baseline during the four hours after administration, which is groundbreaking in its field. Both systolic and diastolic blood pressures were significantly reduced over thirty to sixty minutes and sustained over four hours by an average 25* points from absolute baseline.

Circularity has assembled a Scientific Advisory Board (click for partial list) that includes domestic and international medical thought-leaders in the field of diabetic relief, wound healing, microvascular physiology, neurobiology, endocrinology, amputation prevention, vascular surgery, cardiovascular physiology, and others.

They were asked investigating the administration of gas molecules (gasotransmitters) already found in our bodies naturally in a non-traditional way. Rather than working through inhalation or needle injection, D'OXYVA is administered directly on the skin.

More clinical trials are under way to determine additional benefits, but these results thus far are extremely promising and indicating treatment for a variety of disease states related to deficiencies of blood circulation, autonomic nervous system, and cellular, vascular, and tissue regeneration.

Independent References

(click & read)

Transcutaneous CO2 References


  • Blair DA, Glover WE, McArrdle L. The mechanism of the peripheral vasodilation following carbon dioxide inhalation in man. Clin Sci. 1960;19:407–423.

  • Matz H, Orion E, Wolf R. Balneotherapy in dermatology. Dermatol Ther. 2003;16:132–140. [PubMed]

  • Hartmann BR, Bassenge E, Pittler M. Effect of carbon dioxide-enriched water and fresh water on the cutaneous microcirculation and oxygen tension in the skin of the foot. Angiology. 1997;48:337–343. [PubMed]

  • Hartmann BR, Bassenge E, Hartmann M. Effects of serial percutaneous application of carbon dioxide in intermittent claudication: results of a controlled trial. Angiology. 1997;48:957–963. [PubMed]

  • Toriyama T, Kumada Y, Matsubara T, Murata A, Ogino A, et al. Effect of artificial carbon dioxide foot bathing on critical limb ischemia (Fontaine IV) in peripheral arterial disease patients. Int Angiol. 2002;21:367–73. [PubMed]

  • Brandi C, D'Aniello C, Grimaldi L, Bosi B, Dei I, et al. Carbon dioxide therapy in the treatment of localized adiposities: clinical study and histopathological correlations. Aesthetic Plast Surg. 2001;25:170–4. [PubMed]

  • Brandi C, D'Aniello C, Grimaldi L, Caiazzo E, Stanghellini E. Carbon dioxide therapy: effects on skin irregularity and its use as a complement to liposuction. Aesthetic Plast Surg. 2004;28:222–5. [PubMed]

  • Savin E, Bailliart O, Bonnin P, Bedu M, Cheynel J, et al. Vasomotor effects of transcutaneous CO2 in stage II peripheral occlusive arterial disease. Angiology. 1995;46:785–91. [PubMed]

  • Fabry R, Monnet P, Schmidt J, Lusson JR, Carpentier PH, et al. Clinical and microcirculatory effects of transcutaneous CO2 therapy in intermittent claudication. Randomized double-blind clinical trial with a parallel design. Vasa. 2009;38:213–24. [PubMed]

  • Schmidt J, Monnet P, Normand B, Fabry R. Microcirculatory and clinical effects of serial percutaneous application of carbon dioxide in primary and secondary Raynaud's phenomenon. Vasa. 2005;34:93–100. [PubMed]

  • Duling BR. Changes in microvascular diameter and oxygen tension induced by carbon dioxide. Circ Res. 1973;32:370–6. [PubMed]

  • Bohr C, Hasselbach K, Krogh A. Ueber emen in biologischen Bezuehung wichtigen Einfluss, den die Kohlen saurespannung des Blutes anf dessen Samerstoffbinding ubt. Arch. Physiol. 1904;16:402–412.

  • Riggs A. The nature and significance of the Bohr effect in mammalian hemoglobins. J. Gen. Physiol. 1960;43:737–752. [PMC free article] [PubMed]

  • Tyuma I. The Bohr effect and the Haldane effect in human hemoglobin. Jpn J Physiol. Jpn. J. Physiol. 1984;34:205–216.

  • Jensen FB. Red blood cell pH, the Bohr effect, and other oxygenation-linked phenomena in blood O2 and CO2 transport. Acta. Physiol. Scand. 2004;182:215–227. [PubMed]

  • Hashimoto M, Yamamoto N. Decrease in heart rates by artificial CO2 hot spring bathing is inhibited by beta1-adrenoceptor blockade in anesthetized rats. J. Appl. Physiol. 2004;96:226–232. [PubMed]

  • Yamamoto N, Hashimoto M. Spinal cord transection inhibits HR reduction in anesthetized rats immersed in an artificial CO2-hot spring bath. Int. J. Biometeorol. 2007;51:201–208. [PubMed]

  • Yamamoto N, Hashimoto M. Immersion in CO2-rich water containing NaCl diminishes blood pressure fluctuation in anesthetized rats. Int. J. Biometeorol. 2007;52:109–116. [PubMed]

  • Irie H, Tatsumi T, Takamiya M, Zen K, Takahashi T, et al. Carbon dioxide-rich water bathing enhances collateral blood flow in ischemic hindlimb via mobilization of endothelial progenitor cells and activation of NO-cGMP system. Circulation. 2005;111:1523–9. [PubMed]

  • Raymer GH, Green HJ, Ranney DA, Marsh GD, Thompson RT. Muscle metabolism and acid-base status during exercise in forearm work-related myalgia measured with 31P-MRS. J. Appl. Physiol. 2009;106:1198–1206. [PubMed]

  • Jöbsis FF. Noninvasive, infrared monitoring of cerebral and myocardial oxygen sufficiency and circulatory parameters. Science. 1977;198:1264–1267. [PubMed]

  • Boushel R, Piantadosi CA. Near-infrared spectroscopy for monitoring muscle oxygenation. Acta. Physiol. Scand. 2000;168:615–622. [PubMed]

  • Koga S, Poole DC, Ferreira LF, Whipp BJ, Kondo N, et al. Spatial heterogeneity of quadriceps muscle deoxygenation kinetics during cycle exercise. J. Appl. Physiol. 2007;103:2049–2056. [PubMed]

  • Karalezli N, Ogun CO, Ogun TC, Yildirim S, Tuncay I. Wrist tourniquet: the most patient-friendly way of bloodless hand surgery. J. Trauma. 2007;62:750–754. [PubMed]

  • Miller SH, Lung RJ, Graham WP, Davis TS, Rusenas I. The acute effects of tourniquet ischemia on tissue and blood gas tensions in the primate limb. J. Hand. Surg. Am. 1978;3:11–20. [PubMed]

  • Mancini DM, Bolinger L, Li H, Kendrick K, Chance B, Wilson JR. Validation of near-infrared spectroscopy in humans. J. Appl. Physiol. 1994;77:2740–2747. [PubMed]

  • Chance B, Dait MT, Zhang C, Hamaoka T, Hagerman F. Hagerman, Recovery from exercise-induced desaturation in the quadriceps muscles of elite competitive rowers. Am. J. Physiol. 1992;262:C766–775. [PubMed]

  • Ganong WF. New York: Lange medical Books; 2005. Review of medical physiology. pp. 666–670.

  • Schenkman KA, Marble DR, Burns DH, Feigl EO. Myoglobin oxygen dissociation by multiwavelength spectroscopy. J. Appl. Physiol. 1997;82:86–92. [PubMed]

  • Hilpert P, Fleischmann RG, Kempe D, Bartels H. The Bohr effect related to blood and erythrocyte pH. Am. J. Physiol. 1963;205:337–340. [PubMed]

Shop All Products

Talk to a Representative

Back to Top ^